ALPS Advisors’s Novavax NVAX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-48,989
Closed -$461K – 1261
2026
Q2
$461K Sell
48,989
-132,036
-73% -$1.18M ﹤0.01% 1011
2026
Q1
$1.47M Buy
181,025
+47,593
+36% +$431K 0.01% 465
2025
Q4
$897K Buy
133,432
+57,675
+76% +$435K 0.01% 584
2025
Q3
$657K Sell
75,757
-11,576
-13% -$90.1K ﹤0.01% 626
2025
Q2
$550K Sell
87,333
-26,898
-24% -$178K ﹤0.01% 613
2025
Q1
$732K Sell
114,231
-15,299
-12% -$126K ﹤0.01% 544
2024
Q4
$1.04M Buy
+129,530
New +$1.25M 0.01% 470
2023
Q2
– Sell
-56,775
Closed -$393K – 1021
2023
Q1
$393K Buy
56,775
+3,560
+7% +$32.8K ﹤0.01% 626
2022
Q4
$547K Buy
53,215
+10,502
+25% +$185K ﹤0.01% 575
2022
Q3
$777K Sell
42,713
-3,642
-8% -$158K 0.01% 517
2022
Q2
$2.38M Buy
+46,355
New +$2.4M 0.02% 283

Other funds holding NVAX

ALPS Advisors's NVAX Position: Q3 2026 in Review

ALPS Advisors sold out of Novavax (NVAX) in Q3 2026, closing a stake of 48,989 shares — an estimated $461K sold.

ALPS Advisors first reported a position in NVAX in Q2 2022 and held it in 11 quarters. The position peaked at $2.38M in Q2 2022. 262 funds tracked by Wall St. Rank hold NVAX as of Q3 2026.

  • ALPS Advisors reported no remaining Novavax position as of Q3 2026 after selling out during the quarter.
  • ALPS Advisors sold 48,989 Novavax shares in Q3 2026, an estimated $461K.
  • ALPS Advisors first reported a position in Novavax in Q2 2022 and held it in 11 quarters.
  • ALPS Advisors's Novavax position peaked at $2.38M in Q2 2022.
  • 262 funds tracked by Wall St. Rank held Novavax as of Q3 2026.

Based on ALPS Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.